| Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. | |
| | |
MedLine Citation:
|
PMID: 18809153 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The mechanism underlying rapid, statin-induced event reduction in patients with an acute coronary syndrome (ACS) remains to be clarified. AIM: The primary objective is to compare the efficacy of rosuvastatin 20 mg/day and atorvastatin 80 mg/day in reducing the apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio at three months, in ACS patients. Secondary objectives include a comparison of the effects of early-started rosuvastatin and placebo on inflammatory markers. METHODS: This is a randomized, double-blind, parallel-group study. Patients with non-ST-segment elevation ACS, symptom onset less than 48 h before admission, and for whom a percutaneous coronary intervention is planned, are eligible for inclusion and are randomized into three groups (G1, G2 and G3). The study comprises two double-blind periods. Period 1 starts at hospital admission and lasts until Day 0 (discharge or less or equal to 6 days after admission); patients in G1 receive one tablet of rosuvastatin 20 mg/day and patients in G2 and G3 receive one matching placebo tablet per day. Period 2 starts at Day 0 and lasts for three months; patients in G1 continue to receive rosuvastatin 20 mg/day, patients in G2 receive rosuvastatin 20 mg/day and patients in G3 receive atorvastatin 80 mg/day. Recruitment of 1075 patients will ensure an 80 power to detect a 3% difference in percentage change in the apoB/apoA-1 ratio and a 20% difference in percentage change in high-sensitivity C-reactive protein. RESULTS: Inclusion phase is complete; results will be reported at a later date. CONCLUSION: This is the first trial investigating the effect of statins on apolipoproteins in ACS patients. |
| | |
Authors:
|
Jean-Marc Lablanche; Nicolas Danchin; Michel Farnier; Alain Tedgui; Eric Vicaut; Joaquim Alonso; Peter Crean; Attilio Leone; Joa Morais; Massimo Santini; Muriel Licour; Mohamed Farah; Jean-Claude Tardif |
Related Documents
:
|
10090113 - Forecasting patient outcomes in the management of hyperlipidemia. 10404843 - Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvast... 20573223 - Licaval: combination therapy in acute and maintenance treatment of bipolar disorder. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2008-08-20 |
Journal Detail:
|
Title: Archives of cardiovascular diseases Volume: 101 ISSN: 1875-2136 ISO Abbreviation: Arch Cardiovasc Dis Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-09-23 Completed Date: 2008-12-18 Revised Date: 2011-04-25 |
Medline Journal Info:
|
Nlm Unique ID: 101465655 Medline TA: Arch Cardiovasc Dis Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 399-406 Citation Subset: IM |
Affiliation:
|
Hôpital cardiologique, CHRU de Lille, Lille, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
blood,
drug therapy* Adolescent Adult Apolipoprotein A-I / blood*, drug effects Apolipoproteins B / blood*, drug effects Double-Blind Method Fluorobenzenes / administration & dosage, pharmacology, therapeutic use* Heptanoic Acids / administration & dosage, pharmacology, therapeutic use* Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage, pharmacology, therapeutic use* Pyrimidines / administration & dosage, pharmacology, therapeutic use* Pyrroles / administration & dosage, pharmacology, therapeutic use* Sulfonamides / administration & dosage, pharmacology, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Apolipoprotein A-I; 0/Apolipoproteins B; 0/Fluorobenzenes; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Pyrroles; 0/Sulfonamides; 110862-48-1/atorvastatin; 287714-41-4/rosuvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Is the aortic root dilated in obstructive sleep apnoea syndrome?
Next Document: When and how to assess an asymptomatic ventricular pre-excitation syndrome?